Risk of Adverse Health Outcomes in Patients with Poor Adherence to Cardiovascular Medication Treatment: A Systematic Review
Authors:
- Marcus Vinícius Bolívar MalachiasMMMarcus Vinícius Bolívar Malachias
- Sergio Emanuel KaiserSKSergio Emanuel Kaiser
- Denilson Campos de AlbuquerqueDADenilson Campos de Albuquerque
- Andrea Araújo BrandãoABAndrea Araújo Brandão
- Andrei Carvalho SpositoASAndrei Carvalho Sposito
- Lidia Zytysnky MouraLMLidia Zytysnky Moura
- Lucélia Batista Neves Cunha MagalhãesLMLucélia Batista Neves Cunha Magalhães
- Marco Antonio Mota-GomesMMMarco Antonio Mota-Gomes
- Nadine ClausellNCNadine Clausell
- Paulo César Veiga JardimPJPaulo César Veiga Jardim
- Wilson NadruzWNWilson Nadruz
- Bruno Monteiro BarrosBBBruno Monteiro Barros
Open Access
- 1 January 2024
- journal article
- review article
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 121 (10)
Abstract
Background Cardiovascular diseases (CVD) remain the leading cause of mortality worldwide. Medication adherence is an important issue in managing chronic CVD, directly influencing outcomes and healthcare costs. Objectives This systematic review, supported by the Brazilian Society of Cardiology, evaluates the impact of poor adherence to cardiovascular medications on critical clinical outcomes such as death and cardiovascular events. Methods A comprehensive search was conducted across four databases, including Medline, Embase, Lilacs, and the Cochrane Library. The review included systematic reviews with meta-analyses that reported risk estimates for adherence to cardiovascular medications. Four systematic reviews, each incorporating observational studies, were selected. Results An increase in adherence to medications significantly reduces the risk of cardiovascular events, stroke, and all-cause death. Specifically, a 20% improvement in adherence to antihypertensive, lipid-lowering, and other cardiovascular medications correlated with reductions in cardiovascular events by 7%, 10%, and 9%, respectively; stroke by 17%, 13%, and 18%; and death by 12%, 9%, and 10%. The certainty of the evidence was moderate, suggesting that these effects are likely present. These findings emphasize the importance of enhancing medication adherence to improve clinical outcomes in CVD management. Conclusions Evidence has demonstrated reductions in hard endpoints in both primary and secondary prevention through the control of conditions such as hypertension and elevated LDL cholesterol concentrations, as well as the benefits of antiplatelet therapy in atherosclerotic disease. However, additional studies are needed to better elucidate the relationship between adherence to cardiovascular medications and the improvement of critical clinical outcomes.Keywords
This publication has 21 references indexed in Scilit:
- Cochrane Rapid Reviews Methods Group offers evidence-informed guidance to conduct rapid reviewsJournal of Clinical Epidemiology, 2021
- Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort studyThe Lancet, 2020
- Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus PanelEuropean Heart Journal, 2017
- Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysisThe Lancet, 2016
- Statin adherence and LDL cholesterol levels. Should we assess adherence prior to statin upgrade?European Journal of Internal Medicine, 2015
- Is High‐Intensity Statin Therapy Associated With Lower Statin Adherence Compared With Low‐ to Moderate‐Intensity Statin Therapy? Implications of the 2013 American College of Cardiology/American Heart Association Cholesterol Management GuidelinesClinical Cardiology, 2014
- Proportion and Risk Indicators of Nonadherence to Statin Therapy: A Meta-analysisCanadian Journal of Cardiology, 2012
- Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trialsThe Lancet, 2010
- Fixed-Dose Combinations Improve Medication Compliance: A Meta-AnalysisThe American Journal of Medicine, 2007
- A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50 279 patients at risk for coronary artery diseaseEuropean Heart Journal, 2006